Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
44.75
+0.57 (1.29%)
Sep 28, 2026, 11:48 AM EDT - Market open
Qiagen Revenue
Qiagen had revenue of $535.04M in the quarter ending June 30, 2026, with 0.28% growth. This brings the company's revenue in the last twelve months to $2.10B, up 2.96% year-over-year. In the year 2025, Qiagen had annual revenue of $2.09B with 5.65% growth.
Revenue (ttm)
$2.10B
Revenue Growth
+2.96%
P/S Ratio
4.35
Revenue / Employee
$368,485
Employees
5,700
Market Cap
9.25B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.09B | 111.79M | 5.65% |
| Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
| Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
| Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
| Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
| Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
| Dec 31, 2019 | 1.53B | 24.58M | 1.64% |
| Dec 31, 2018 | 1.50B | 84.31M | 5.95% |
| Dec 31, 2017 | 1.42B | 79.55M | 5.95% |
| Dec 31, 2016 | 1.34B | 57.01M | 4.45% |
| Dec 31, 2015 | 1.28B | -63.79M | -4.74% |
| Dec 31, 2014 | 1.34B | 42.79M | 3.29% |
| Dec 31, 2013 | 1.30B | 47.53M | 3.79% |
| Dec 31, 2012 | 1.25B | 84.71M | 7.24% |
| Dec 31, 2011 | 1.17B | 82.32M | 7.57% |
| Dec 31, 2010 | 1.09B | 77.61M | 7.69% |
| Dec 31, 2009 | 1.01B | 116.85M | 13.09% |
| Dec 31, 2008 | 892.98M | 243.20M | 37.43% |
| Dec 31, 2007 | 649.77M | 184.00M | 39.50% |
| Dec 31, 2006 | 465.78M | 67.38M | 16.91% |
| Dec 31, 2005 | 398.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.29B |
| Charles River Laboratories International | 4.00B |
| Revvity | 2.91B |
| Medpace Holdings | 2.78B |
| RadNet | 2.27B |
| Sotera Health Company | 1.22B |
| Guardant Health | 1.18B |
| Veracyte | 561.90M |
QGEN News
- 5 hours ago - Qiagen: QIAstat-Dx bloodstream infection portfolio now available to U.S. labs - TheFly
- 10 hours ago - QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel - Business Wire
- 3 days ago - Qiagen launches QIAmini - TheFly
- 3 days ago - QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation - Business Wire
- 9 days ago - QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board - Business Wire
- 11 days ago - Qiagen attracts interest from KKR, Advent, TPG, Manager Magazin reports - TheFly
- 12 days ago - Qiagen Transcript: 2026 Global Healthcare Conference - Transcripts
- 13 days ago - Qiagen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts